US2003023074A1PendingUtilityA1

Galanin receptor GALR3 and nucleotides encoding same

Assignee: MERCK & CO INCPriority: Dec 17, 1997Filed: Aug 6, 2002Published: Jan 30, 2003

Est. expiryDec 17, 2017(expired)· nominal 20-yr term from priority

Inventors:Andrew D. Howard Margaret A. Cascieri Roy G. Smith Kathleen Sullivan Carina Tan Leonardus H. T. Van Der Ploeg Kevin R. Lynch

C07K 14/72A61K 38/00

PatentIndex Score

Cited by

References

Claims

Abstract

A new galanin receptor, GALR3, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.

Claims

exact text as granted — not AI-modified

What is claimed:  
     
         1 . Galanin receptor 3 (GALR3), substantially free from associated proteins, or a GALR3-like receptor, wherein the GALR3-like receptor shares at least about 40% homology to GALR3 and has substantially the same biological activity.  
     
     
         2 . A GALR3-like receptor according to  claim 1 , which shares at least about 50% homology to a GALR3.  
     
     
         3 . A GALR3-like receptor according to  claim 1 , which shares at least about 75% homology to a GALR3.  
     
     
         4 . A GALR3-like receptor according to  claim 1 , which shares at least about 85% homology to a GALR3.  
     
     
         5 . A GALR3 in accordance with  claim 1  which is human.  
     
     
         6 . A GALR3 in accordance with  claim 1  which is rat.  
     
     
         7 . GALR3 according to  claim 1  which is shown in FIG. 1.  
     
     
         8 . GALR3 according to  claim 1  which is shown in FIG. 3.  
     
     
         9 . GALR3 according to  claim 1  which is shown in FIG. 8.  
     
     
         10 . A nucleic acid, substantially free from associated nucleic acids, which encodes a GALR3 or a GALR3-like receptor which is at least about 40% homologous to GALR3 and which has substantially the same biological activity.  
     
     
         11 . A nucleic acid encoding a GALR3-like receptor according to  claim 10 , wherein the GALR3-like receptor shares at least about 50% homology to a GALR3.  
     
     
         12 . A nucleic acid encoding a GALR3-like receptor according to  claim 10 , wherein the GALR3-like receptor shares at least about 75% homology to a GALR3.  
     
     
         13 . A nucleic acid encoding a GALR3-like receptor according to  claim 10 , wherein the GALR3-like receptor shares at least about 85% homology to human GALR3.  
     
     
         14 . A nucleic acid according to  claim 10  which is DNA.  
     
     
         15 . A vector comprising the nucleic acid of  claim 13 .  
     
     
         16 . A host cell comprising the nucleic acid of  claim 10 .  
     
     
         17 . A method of determining if a compound is a GALR3 ligand comprising contacting the compound and GALR3 and determining if binding occurs.  
     
     
         18 . A method of identifying a compound that modulates GALR3 receptor activity, comprising: 
 (a) culturing cells expressing GALR3 receptor in the presence of the compound; and    (b) measuring GALR3 receptor activity or second messenger activity.    
     
     
         19 . A method according to  claim 18  wherein the cells are transformed to express a GALR3 receptor.

Join the waitlist — get patent alerts

Track US2003023074A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.